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Switzerlanda b s t r a c tHeart failure is a worldwide epidemic and represents a major cause of morbidity and mortality. Current clinical therapies for heart disease
prolong survival by protecting the viable muscle, but they are unable to replenish lost cardiomyocytes to restore function. Over the last
decade, the notion of promoting cardiac regeneration has engendered considerable research interest. New strategies envisage the transfer
of stem cells into the damaged myocardium, the mobilization of cardiac precursor cells, the promotion of cardiomyocyte proliferation
in situ and direct reprogramming of non-cardiac cells into electromechanically coupled cardiomyocytes. The molecular and cellular
mechanisms underpinning these different regenerative avenues are under the control of integrated transcriptional programs, which are
ultimately dependent on epigenomic reprogramming and reorganization of the genome nuclear architecture. Today, it is becoming
evident that regulatory noncoding RNAs play fundamental roles in all these aspects of gene regulatory network activity. In particular,
thousands of long noncoding RNAs are dynamically expressed across the entire genome during lineage-speciﬁc commitment, special-
ization, and differentiation, as well as during the response to environmental cues. Here, we review this emerging landscape, focusing
particularly on a unique class of lncRNA emerging from enhancer sequences, the enhancer-associated lncRNAs, in the context of cardiac
regeneration. We propose that characterizing and manipulating these enhancer-associated transcripts could provide a novel approach to
awaken the dormant regenerative potential of the adult mammalian heart. Ultimately, this could lead to targeted noncoding RNA-based
enhancer therapies to improve effectiveness of current regenerative strategies and provide new avenues for repair.
& 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Coronary artery disease is the most frequent cardiovascular
disorder and leads to acute myocardial infarction. Myocardial
infarction frequently progresses into maladaptive cardiac
remodeling and congestive heart failure, which therefore
affects millions of people worldwide and is a major cause of
morbidity and mortality [1]. Despite several efforts to improve
treatments during the acute phase of myocardial infarction,
the WHO estimates that rising life expectancy coupled with
adverse trends in cardiovascular risk factors, including1016/j.tcm.2015.01.014
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thierry.pedrazzini@chuv.ch (T. Pedrazzini).obesity and type II diabetes, might lead to a doubling of the
incidence of cardiovascular disease by 2050. Currently, trans-
plantation remains the only therapeutic option for end-stage
heart failure. However, the lack of organ donors limits the
access to transplantation to a small number of patients each
year. It is therefore urgent to develop alternative strategies to
treat heart failure patients. In this context, induction of
cardiac regeneration in the damaged heart could represent
an attractive therapeutic approach [2,3]. This will only be
possible if the pathways and underlying molecular mecha-
nisms important for inducing repair are identiﬁed.pen access article under the CC BY-NC-ND license
from the Swiss National Science Foundation, Switzerland (T.P.;
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disease has engendered a lot of attention. From the old dogma,
which assumed that the postnatal heart had no capacity to
generate new cardiomyocytes, we have gradually shifted to a
general acceptance that the heart demonstrates some ability
for self-renewal. However, the rate of cardiomyocyte produc-
tion in the adult heart is extremely low [4]. In addition, the
damaged heart has poor regenerative potential and heart
failure develops following injury [5]. Nevertheless, these ﬁnd-
ings created great expectations in the community. Indeed, if
one assumes that the heart possesses the necessary elements
for regeneration, strategies can be envisaged to reinforce basic
cellular and molecular mechanisms and tip the balance
toward more regenerative repair [3]. There are principally
two strategies to induce regeneration in the adult heart. First
of all, precursors of cardiomyocytes can be transferred into the
damaged heart, hoping that the cardiac environment provides
the indispensable factors to eventually promote engraftment,
terminal differentiation into mature cardiomyocytes, and
electro-mechanical coupling to the host tissue (Fig. 1A). The
main challenge in cell therapies for heart disease is to identify
a suitable source of cardiac precursors cells (CPC). Therefore,
several different cell types have been evaluated. Embryonic
stem (ES) cells and induced pluripotent stem (iPS) cells are
unlimited sources of precursors [2]. In particular, the produc-
tion of iPS cells represents a tremendous opportunity for
developing patient-speciﬁc cell therapies [6]. However, speci-
ﬁcation and differentiation must be tightly controlled in order
to not produce unwanted cell types in the heart and cause
major adverse effects. On the other hand, adult stem cells also
represent suitable sources of precursors. Ideally, these cells
should be isolated from the heart. So-called cardiac stem cells
and CPC have indeed been identiﬁed in the myocardium, but
these cells are rare and their exact nature remains to be
completely established [7]. In addition, their real potential in
cell replacement therapies for heart failure still needs to be
demonstrated. Nevertheless, direct isolation of autologous CPC
from the adult human heart would considerably reduce the
problems associated with immune rejection following transfer.
The second basic strategy consists in activating regenerative
pathways in the heart (Fig. 1B). Resident CPC could be
mobilized, induced to proliferate, and stimulated to differ-
entiate into mature cardiomyocytes directly in situ. Inspiration
comes from pathways governing cardiomorphogenesis in the
developing heart [8]. In addition to candidate approaches
targeting developmental pathways, more unbiased methods
have also been used to identify mechanisms that are able to
force cardiomyocytes to reenter the cell cycle [9]. Proliferation
of dedifferentiated cardiomyocytes represents the basis of
regeneration in species like the Zebraﬁsh or in the neonatal
mammalian heart [10–12]. Finally, researchers have recently
used induced reprogramming to convert differentiated cells of
the heart, speciﬁcally cardiac ﬁbroblasts, directly into cardio-
myocytes [13]. Using this approach, one can bypass iPS cell
production to directly obtain the cell type of interest. More-
over, direct reprogramming can also be demonstrated follow-
ing induction in vivo, within the heart [14,15]. Direct
reprogramming of somatic cells into cardiomyocytes certainly
holds great promise in cardiac regenerative medicine and
justiﬁes further investigation.Although the current regenerative strategies have distinct
characteristics linked to proliferation, differentiation, and
reprogramming, they all fundamentally depend on overlap-
ping cellular and molecular processes [16]. The gene regu-
latory networks that govern these processes are under the
control of the integrated activity of core cardiac lineage,
specifying transcription factors including Mesp1, Nkx2.5,
Mef2c, Gata4, Tbx5, and Hand2. These transcription factors
interact in a combinatorial and self-reinforcing manner at
target cis-regulatory modules to elicit speciﬁc temporal and
spatial gene programs [16–18]. Coordinated binding of the
core transcription factors is coupled with dynamic remodel-
ing of the underlying chromatin, leading to global epigenomic
reprogramming and reorganization of the genome nuclear
architecture [19]. These genomic processes dictate protein-
coding gene expression that is ultimately responsible for
cellular fate, phenotype, and behavior. Importantly, the
regulation of the proteome, the transcriptome, the epige-
nome, and the nuclear architecture is highly integrated to
coordinate outputs of otherwise disparate molecular net-
works. Within this context, it has recently emerged that the
noncoding portion of the genome generates a vast repertoire
of noncoding RNAs with regulatory function on cell-speciﬁc
gene networks [20,21]. An important subclass of these tran-
scripts is derived from enhancer sequences [22,23]. This
exciting discovery opens the new era of enhancer therapy
to treat diseases by modulation of enhancer-associated non-
coding RNAs and subsequently their target transcriptional
programs.The regulatory role of the noncoding genome
The analysis and interpretation of gene regulatory network
activity have traditionally been protein-centric. However,
recent high-throughput sequencing technologies have begun
to illuminate our understanding of the human genome.
Speciﬁcally, only 1–2% of the genome appears to code for
proteins. The remaining 98% represents the noncoding por-
tion of the genome [20,21]. This genomic “dark matter” is
dynamically transcribed, producing thousands of RNAs with
no protein-coding potential, globally named noncoding RNAs
(ncRNAs). Emerging evidence indicates that these noncoding
transcripts are responsible for complexity in gene regulation,
which underpins specialized biological processes during
development and in adulthood [24]. The vast majority of
the 20,000 human proteins are similar in number and orthol-
ogous in function to those found in distantly related species.
In contrast, the number of noncoding genes is proportional to
the developmental complexity among animals. Nevertheless,
an increasing number of studies are demonstrating that these
structurally diverse ncRNAs control every aspect of gene
regulatory network activity, including transcriptional control,
post-transcriptional gene regulation, epigenetic targeting,
and nuclear genome organization [25]. In this context, the
roles of ncRNAs in cardiac development, disease, and ulti-
mately regeneration remain to be deﬁned. However, incorpo-
rating ncRNAs within the logic governing cardiac gene
regulatory networks provides unprecedented opportunities
for therapeutic intervention and may facilitate the promotion
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Fig. 1 – Current avenues for inducing regeneration in the damaged heart. The putative functional implication of lncRNAs is
indicated by arrows. (A) Cell replacement therapies for heart disease rely on the identiﬁcation of appropriate sources of
cardiac precursor cells (CPC). These cells can be isolated from the heart or derived from pluripotent stem cells following
controlled differentiation in vitro. Embryonic stem cells (ESC) and induced pluripotent stem cells (iPSC) represent two types of
pluripotent stem cells. Somatic cells such as ﬁbroblasts can be reprogrammed to give rise to iPSC. In addition, ﬁbroblasts can
also be directly reprogrammed into cardiomyocytes. These different cell types can all be transferred back into the heart for
potentially replenishing the cardiomyocyte pool lost after injury. (B) Cardiac regeneration can also be induced by activating
appropriate regenerative pathways within the heart. The target populations in this case are CPC, cardiomyocytes, or cardiac
ﬁbroblasts. Mobilization of CPC and induction of cardiogenic differentiation are usually achieved by reactivation of
developmental pathways in the adult heart (1). In another approach, cardiomyocytes can be induced to reenter the cell cycle
following partial dedifferentiation (1). Finally, direct reprogramming of cardiac ﬁbroblasts represents another way to produce
new cardiomyocytes in the injured heart following intramyocardial transfer of inducing factors (2).
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review is therefore to provide insights into the roles of long
noncoding RNAs (lncRNAs) within the cardiac gene regulatory
network and their potential in cardiac regenerative therapies.
The RNAs produced by the noncoding genome are rich and
diverse in biogenesis, structure, and function [25]. They are
currently parsed based on size, with small regulatory ncRNAsdeﬁned as those that are less than 200 nucleotides in length
and long ncRNAs (lncRNAs) that are more than 200 nucleo-
tides in length [26]. Many of the originally identiﬁed ncRNAs,
including transfer, ribosomal, small nuclear, and small nucle-
olar RNAs have well-established roles as structural and
functional components of the splicing and translational
machineries. Recently, much interest has arisen in a
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directly affect the function and expression of protein-coding
genes. These small transcripts include PIWI-interacting
ncRNAs, endogenous small interfering RNAs, and microRNAs
(miRNAs). With relevance to cardiac regeneration, miRNAs
represent the most extensively studied class of small regu-
latory ncRNAs [27]. These 22–23 nucleotide single-stranded
RNAs guide RNA-induced silencing complexes to their target
messenger RNAs (mRNAs). Recognition involves partial
sequence complementarity, primarily with the target gene
30UTR. Indeed, miRNAs are predicted to mediate ﬁne-tuning
of coding gene expression via post-transcriptional gene
silencing of up to 60% of mammalian mRNAs. Not surpris-
ingly, miRNAs have been shown to play critical roles during
cardiac development, pathological remodeling, and cardiac
regeneration [28]. For instance, miRNAs have important
regulatory roles in directing cell fate decision during cardio-
genesis while their expression is often regulated by important
cardiac transcription factors. Interestingly, cardiac biological
processes implicated in regeneration are all signiﬁcantly
inﬂuenced by miRNA-dependant regulatory networks. These
include cardiac speciﬁcation and differentiation, cardiomyo-
cyte dedifferentiation and proliferation, and direct reprog-
ramming of cardiac ﬁbroblasts into cardiomyocytes. For
instance, combinations of muscle-speciﬁc miRNAs, namely
miR-1, miR-133, miR-208, and miR-499, are sufﬁcient to
reprogram mouse ﬁbroblasts into cardiomyocytes in vitro
and in vivo, reducing infarct scar size and improving cardiac
performance [29,30]. In addition, a number of miRNAs par-
ticipate in pathophysiological remodeling in the heart. Many
miRNAs that are modulated in the stressed myocardium are
also implicated in induced cardiogenesis, suggesting that
miRNA-mediated regenerative pathways could be activated
in cardiac tissues upon damage. This has been the subject of
recent reviews [27,28], and we will therefore focus herein on a
newly identiﬁed class of ncRNAs, namely lncRNAs.Long noncoding RNAs
LncRNAs comprise the bulk of the noncoding transcriptome
[20,21]. They represent a structurally and functionally diverse
class of regulatory ncRNAs, which can range up to tens or
even hundreds of thousands of nucleotides in size. They may
or may not be subject to polyadenylation and alternative
splicing. LncRNAs can be nuclear or cytoplasmic, although
the most investigated to date are generally enriched in the
nucleus. Their expression in particular subcellular compart-
ments is probably related to speciﬁc function associated with
particular lncRNAs. Classiﬁcation of lncRNAs is currently
quite primitive and is primarily based on their genomic
location. For example, long intergenic noncoding RNAs are
located between coding genes within intergenic space, not
overlapping exons of other coding genes. LncRNAs can also
reside within introns of coding genes occasionally overlap-
ping with and sharing exons. An early characterized class
includes the so-called natural antisense transcripts, which
are produced from the opposite strand of a coding gene. Their
transcription initiation site is typically downstream relative
to that of the coding gene. In addition to their geographicaldiversity, lncRNAs are highly versatile macromolecules that
can pair with other RNA templates or with DNA to form
triplex structures [25]. These molecules can also interact with
a vast repertoire of proteins, highlighting their tremendous
regulatory potential. A number of examples from different
ﬁelds of science allowed the delineation of speciﬁc modes of
lncRNA action. In particular, lncRNAs can act as molecular
signals to target speciﬁc elements in both the transcriptome
and the genome [24]. They also can act as speciﬁc molecular
scaffolds for protein–protein interactions and have roles as
molecular decoys for both nucleic acids and proteins [25].
Having said this, lncRNAs are emerging primarily as important
regulators of gene expression at the transcriptional and post-
transcriptional level. They demonstrate distinctive roles in
modulating tissue-speciﬁc epigenomic states and nuclear organ-
ization, which are critical for correct gene regulatory network
activity [24]. Several characteristics of lncRNAs make them ideal
molecules to provide the nucleus with a catalog of molecular
“address codes” to guide epigenetic and transcriptional regula-
tory events. In particular, lncRNAs can rapidly and efﬁciently
operate both in cis, at their site of transcription, and in trans, at
remote locations in the genome (Fig. 2). For instance, a subclass
of lncRNAs associated with active enhancers has recently been
found to activate neighboring genes in cis using mechanisms
involving chromatin looping between the enhancer sequences
and their target gene (see below). However, many characterized
lncRNAs act primarily in trans as decoys or recruiters for tran-
scription factors and chromatin-remodeling complexes to acti-
vate or silence speciﬁc expression programs [24]. LncRNAs have
particular afﬁnity with RNA-binding proteins such as compo-
nents of the Trithorax and Polycomb complexes. In addition,
other trans-regulatory roles have also been identiﬁed. Some
lncRNAs have a signiﬁcant impact on mRNA degradation, trans-
lation, or splicing by binding to proteins or components of
ribonucleoprotein complexes [25]. Finally, some lncRNAs have
been reported to function as miRNA sponges, targeting these
small regulatory ncRNAs away from their target mRNAs [31].
This establishes so-called competitive endogenous networks, in
which expression of each participant is closely dependent on
expression of the two other members.
One unique characteristic associated with lncRNAs is that
they exhibit richer tissue speciﬁcity when compared to coding
genes and small regulatory ncRNAs [25]. This is in particular the
case in the heart [32]. This suggests that one primary function
of lncRNAs during cell speciﬁcation and differentiation is to
modulate combinations of ubiquitously expressed chromatin-
modifying complexes in a highly cell-speciﬁc manner. In turn,
this governs the epigenomic state of target genomic regions and
promotes adoption of particular fate. Interestingly, many
lncRNAs appear to function during development to repress
non-appropriate gene networks through the recruitment of
repressive chromatin-modifying complexes at speciﬁc sites
within the genome [33]. Therefore, specialization appears to
occur via lncRNA-mediated restriction of particular states
rather than activation of alternative states. Moreover, global
reorganization of the epigenome and of the nuclear architecture
is crucial for induced reprogramming to a pluripotent state, i.e.,
production of induced pluripotent stem cells (iPS) [34]. A canon-
ical example is the lncRNA known as “Regulator of Reprogram-
ming” (linc-ROR). Overexpression or depletion of this lncRNAs
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Fig. 2 – Role of enhancer-associated lncRNAs in cis- and trans-regulation of coding gene expression. (A) Enhancers activate
proximal (1) and distal genes at remote locations in the genome (2) and (3). (B) Enhancer-associated lncRNAs exert regulatory
function on coding gene expression via diverse mechanisms. In classic cis-regulation, a nascent and tethered enhancer-
associated lncRNA induces and stabilizes DNA looping between the enhancer and the promoter of the adjacent coding
gene (1). In a similar cis-regulatory mechanism, the nascent and tethered enhancer-associated lncRNAs promote association
of the enhancer with a promoter positioned at a remote location in the genome (2). In classic trans-regulation, the enhancer-
associated lncRNAs are released from their site of transcription and activate remote gene promoters via recruitment of the
transcription machinery (3). LncRNAs can have other trans-regulatory functions, e.g., cytoplasmic functions (4).
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blasts to induced pluripotent stem (iPS) cells [35]. The capacity
of lncRNAs to control epigenomic remodeling and organization
of the nuclear architecture is therefore key for lineage-speciﬁc
transcriptional regulation during cellular speciﬁcation, differ-
entiation, and reprogramming, all processed that are central to
elaborate a coordinated regenerative response.Enhancers: Key information processing units
within the genome
Tight control of cell proliferation and functional specializa-
tion is fundamental for biological processes that are
implicated in developmental and adaptive responses in
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developmental and environmental cues by executing differ-
ential transcriptional programs from a single set of genetic
material. Within the gene regulatory networks, enhancers are
the primary information processing units that enable specif-
icity of transcriptional gene programs [36]. Enhancers were
initially characterized as cis-regulatory DNA elements that
activate target genes over large distances in an orientation-
independent manner [37]. They contain clusters of binding
sites for lineage-determining transcription factors (TFs),
which thereby regulate gene expression in a temporal and
spatial fashion. Therefore, cardiac-specifying TFs and chro-
matin regulators coordinate the activation and repression of
complex transcriptional networks that underpin cardiac gene
regulatory networks. This primarily occurs at enhancer
sequences, which selectively recruit TFs and integrate spe-
ciﬁc chromatin-state transitions to elicit appropriate cellular
responses. Current estimates based on the use of high-
throughput epigenomic screens suggest that more than
1 million putative enhancers exist in the human genome,
vastly outnumbering protein-coding genes. On average, each
coding gene is potentially regulated by tens of enhancers.
This observation has led many to suggest that the complexity
of enhancer utilization is responsible for the highly complex
gene expression programs required for specialized develop-
mental programs.
Dynamic regulation of lineage-determining transcriptional
programs is particularly evident during cardiac development
where complex patterns of gene expression are exquisitely
modulated during cardiac morphogenesis [18]. A genome-
wide epigenomic screen identiﬁed 3000 cardiac enhancers in
the developing mouse heart at embryonic day 11.5, based on
cardiac-speciﬁc enrichment of p300 [38]. Accordingly, disrup-
tion of cardiac gene regulatory networks at the level of
transcription factors, chromatin-remodeling complexes, and
enhancer sequences underpins congenital heart disease and
susceptibility to acquired adult heart pathologies [18]. Con-
sistent with these ideas, the epigenome has been recently
proﬁled at four stages during differentiation of mouse embry-
onic stem cells into cardiomyocytes, recapitulating develop-
mental programs [39]. Through interrogating speciﬁc
chromatin marks (H3K4me1 and H3K27Ac) to parse poised
vs. active enhancers, over 80,000 enhancers were identiﬁed
across the developmental time course in vitro. Interestingly,
the sets of active enhancers were largely unique, even in
closely related cellular lineages, demonstrating that rapid
stage-speciﬁc chromatin-state transitions occur at enhancer
regions during cardiac speciﬁcation, differentiation, and
maturation. In addition, some Mendelian diseases have been
shown to occur as consequences of disruption of enhancer-
binding TF function [40]. Mutations within noncoding DNA
elements, including enhancers, also have similar develop-
mental consequences. Recent studies highlight that disrup-
tion of enhancer activity by trait-associated single nucleotide
polymorphisms (SNPs) is a common phenomenon in complex
diseases. For example, recent genome-wide studies proﬁling
enhancers in nine cell types demonstrated that trait-
associated SNPs were enriched speciﬁcally in enhancers
active within biologically relevant cell types [41]. These data
suggest that human genetic variation linked to speciﬁc traitsand disease can contribute to phenotypes by affecting
enhancer activity and subsequently gene regulatory networks
hardwired by the affected enhancers.
Recently, investigators have identiﬁed regions of the genome,
where sets of enhancers are clustered together. These
enhancers are currently termed “super” or “stretch” enhancers
[42,43]. They are characterized by a 10-fold higher median
length than regular enhancers, enrichment for lineage-speciﬁc
TFs, and greater association with chromatin-remodeling fac-
tors. Importantly, these super-enhancers produce higher levels
of enhancer-associated ncRNAs as compared to canonical
enhancers. Furthermore, gene encoding master regulators of
cell identity and specialization are located proximally to super-
enhancers. Approximately 250 super-enhancers were found to
be active within the adult human left ventricle. These were
signiﬁcantly enriched with genetic variants associated with
cardiac electrocardiographic traits [41]. Two recent studies used
global epigenomic screens to examine cardiac enhancer
dynamics during pathological remodeling in the heart. One
study assessed distal GATA4-bound enhancer dynamics during
adult heart homeostasis [44], while the other assessed the
dynamics of enhancer activity, deﬁned by extensive acetylation
of histone 3 lysine 27 (H3K27ac), during pressure overload-
induced cardiac hypertrophy [45]. Both studies demonstrate
that context-speciﬁc transcription factor occupancy underlies
stage-speciﬁc transcriptional events during cardiac homeostasis
and disease. Moreover, the epigenetic landscape at enhancers is
a key determinant of gene expression reprogramming in
cardiac hypertrophy. These ﬁndings place enhancers as the
central units within the gene regulatory networks that underpin
these maladaptive processes. Interestingly, these data are also
consistent with reactivation of developmental pathways in the
stressed heart. Enhancer remodeling is therefore likely to be the
key regulatory determinant for the reactivation of dormant
regenerative pathways within the adult mammalian heart.Enhancer-associated long noncoding RNAs
Enhancers positively regulate the expression of their target
genes via remodeling of the local epigenetic landscape and the
formation of three-dimensional chromatin loops to facilitate
RNA polymerase II (RNAPII) initiation and elongation at target
gene transcriptional start sites (Fig. 2) [46]. As discussed above,
these critical genomic regulatory processes are under the
control of regulatory ncRNAs. Over recent years, evidence has
emerged of pervasive RNA transcription at active enhancer
sequences during different cellular contexts [22]. Original
reports characterized broad patterns of transcription at active
enhancers in neurons and T cells. Subsequently, approaches
able to detect nascent transcripts conﬁrmed the production of
enhancer-associated lncRNAs (elncRNAs) in prostate and
breast cancers. These reports demonstrated that RNAPII com-
plexes were enriched at enhancer elements and rapidly
responded to signal transduction via elncRNA transcription.
The integration of various genomic technologies, including
ChIP-Seq, RNA-Seq, and chromosome conformation capture,
has allowed deﬁning the properties of elncRNAs. Enhancer-
associated lncRNAs are transcribed from enhancer regions
characterized by high monomethylation of histone H3 lysine 4
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expression of elncRNAs correlates also with the activation
of the enhancers as indicated by H3K27Ac [47]. Generally,
elncRNAs exhibit similar levels of transcription as compared
to mRNAs but exhibit much shorter half-lives. Importantly,
developmental and signal-dependent changes in elncRNA
expression are highly correlated with expression of target
genes, in particular in the heart [47–49]. Thus, elncRNAs are
dynamically expressed upon developmental differentiation
cues and upon signal transduction events orchestrated by
signal-dependant transcription factors or nuclear receptors.
Interestingly, elncRNAs exist as two primary transcripts [47].
One is unidirectional, multi-exonic, spliced, and polyadenylated
elncRNAs. The other is bidirectionally transcribed and non-
polyadenylated. The latter is more common and found at most
enhancers. Despite these pieces of evidence, controversy per-
sists as to whether elncRNA production is required for enhancer
activity. However, a number of recent studies have demon-
strated that using loss-of-function approaches that targeted
degradation of elncRNA is sufﬁcient to reduce expression of
adjacent coding genes [50,51]. In some instances, depletion of
elncRNAs results in reduced enhancer–promoter chromatin
looping [52]. Therefore, elncRNAs could play a role in the
initiation and stabilization of the loop, which ultimately dic-
tates the integration of enhancers within gene regulatory net-
works. In contrast, many elncRNAs are not required for the
looping process itself. Instead, elncRNAs appear to function
once the loop is already formed, to facilitate RNAPII pause
release at target transcriptional start sites and to promote
transcriptional elongation [53]. However, both mechanisms
suggest cis-regulatory function for elncRNAs. Indeed, the main
characteristics of elncRNAs, including their low expression,
their absence at genomic regions other than their site of
transcription, and the minimal effects of loss-of-function on
non-adjacent coding genes, are mainly consistent with a pre-
dominant cis mechanism of action. Therefore, elncRNAs could
exert their function via promoting direct interactions between
enhancers and neighboring or distal genomic regions, reﬁned
within speciﬁc three-dimensional domains (Fig. 2). Neverthe-
less, this does not rule out the possibility of classic trans-
regulatory function for elncRNAs. Classic trans-regulation is
suggested by the fact that depletion of certain elncRNAs leads
to change in the expression of a greater number of genes than
its predicted target gene alone [22]. Considering the roles that
elncRNAs have in inducing nuclear architecture reorganization,
trans-regulatory function might represent the capacity of
elncRNAs to stabilize the genome in topological three-
dimensional domains, favoring the adoption of particular cell
fate during development and cellular specialization. Controlled
remodeling of such nuclear domains might be of major impor-
tance to hardwire cardiac gene regulatory networks for reprog-
ramming and induction of a regenerative response in the adult
human heart.Enhancer-associated long noncoding RNAs in
cardiac differentiation and in development
LncRNAs are emerging as key regulators for both maintaining
stemness in ES and precursor cells and specifying these cellstoward the three primary germ layers, i.e., the mesoderm,
endoderm, and ectoderm. In a pioneering study, these prop-
erties were systematically investigated via a loss-of-function
approach in mouse ES cells [54]. Most of the functional
lncRNAs were shown to bind diverse chromatin reader,
writer, and eraser regulatory protein complexes to control
speciﬁcation and specialization into one of the three germ
layers and their derived lineages. In particular, some of the
identiﬁed lncRNAs determine speciﬁcation into the meso-
derm through repression of non-appropriate cell fates. How-
ever, characterization of lncRNAs in cardiac lineage
commitment is still in its infancy. Here, we will highlight
recently described lncRNAs, speciﬁcally those associated with
enhancer sequences that have been implicated in cardiac
biology.
Despite not being directly associated with a cardiac
enhancer, the lncRNA Braveheart (Bvht, AK143260) is a
lncRNA transcribed from an important regulatory locus,
which has been previously shown to be rich with heart-
speciﬁc enhancers [55]. Bvht was discovered based on its
unique expression pattern during cardiac differentiation in
mouse ES cells. However, Bvht is also enriched in the adult
heart as compared to other tissues, suggesting that it repre-
sents an important lncRNA for cardiac lineage speciﬁcation
and differentiation. Indeed, Bvht loss-of-function in mouse
ES cells resulted in perturbed differentiation and reduced
formation of cardiomyocytes. Interestingly, Bvht appears to
be directly upstream of Mesp1, an essential transcription
factor that marks early cardiac precursor cells during devel-
opment. Mesp1-positive precursor cells have the capacity to
generate all cell types of the heart, including endothelial cells,
smooth muscle cells, and cardiomyocytes. Therefore, Bvht,
via its regulation of Mesp1, is responsible for the correct
temporal activation of cardiogenic lineage-determining TFs
such as Nkx2-5, Hand1, Hand2, Tbx2, Gata6, and Gata4.
Through this critical modulation of the cardiac-specifying
gene regulatory network, Bhvt could be necessary for the
lineage transition from nascent to cardiac mesoderm and the
subsequent differentiation into cardiomyocytes. Functionally,
Bvht appears to act in trans, by interacting with SUZ12, an
important component of the PRC2 complex. Interestingly,
many of the key TFs within the cardiac gene regulatory
network are targets of PRC2 [56]. Cardiogenic differentiation
therefore requires the selective loss of PRC2 binding at
subsets of these core regulatory TFs, including Nkx2-5, Gata6,
Hand1, Hand2, and importantly Mesp1. Since Bhvt depletion
maintains enrichment of PRC2 and its associated histone
modiﬁcation, H3K27me3, at the promoters of these critical
cardiac TFs, it suggests that Bvht may function as a decoy for
PRC2 to promote activation of cardiac lineage-determining
genes. These initial ﬁndings support the notion for Bhvt, and
lncRNAs in general, to be powerful regulatory molecules
capable of inducing cardiac speciﬁcation and differentiation.
However, caution should be taken as a conserved Bhvt tran-
script has not been identiﬁed in humans, suggesting that
other convergent mechanisms exist.
Another regulator of embryonic heart development has also
recently been described. Fendrr (Foxf1 adjacent noncoding
developmental regulatory RNA; ENSMUSG00000097336) is spe-
ciﬁcally expressed in the lateral plate mesoderm of the
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give rise to structures of the ventral body wall and the heart.
Integration of a premature PolyA signal to disrupt the Fendrr
transcript in transgenic mice resulted in embryonic lethality as
a consequence of ventral body wall defects and hypoplastic
cardiac ventricles. As observed with Bvht, cardiac lineage-
determining TFs, including Gata6 and Nkx2-5, were differ-
entially modulated in Fendrr-null hearts. Consistent with a
role as an enhancer-associated lncRNA with cis-regulatory
action, the proximal TF Foxf1a was ectopically expressed in
Fendrr-null embryos. Furthermore, Fendrr was shown to
interact with both activating (Trithorax) and repressive
(PRC2) chromatin modiﬁers, targeting these complexes to the
promoters of key TFs controlling mesodermal and cardiac
speciﬁcation. Therefore, the capacity to guide cardiac speciﬁ-
cation makes lncRNAs such as Bvht and Fendrr interesting
targets for inducing regeneration. For instance, direct reprog-
ramming of non-myocyte cells into cardiomyocytes, a promis-
ing therapy currently under investigation, is associated with
differential methylation of H3K27 at cardiac coding gene
promoters, a process under the control of PRC2, potentially
implicating elncRNAs in cardiomyocyte reprogramming.
Our laboratory has recently assessed transcription from bona
ﬁde developmental cardiac enhancers that have been identiﬁed
using an epigenomic screen in developing embryos [38,49]. The
enhancer nature of the identiﬁed sequences was previously
conﬁrmed in transgenic LacZ reporter mice. Individual sequen-
ces exhibit enhancer activity speciﬁcally within the embryonic
heart and are dynamically transcribed during cardiac differ-
entiation. In addition, elncRNA expression correlates expression
of neighboring genes, consistent with cis-regulation. Impor-
tantly, depletion of elncRNAs results in reduced expression of
enhancer target genes. For instance, activity at the enhancer
named mm85 produces an associated transcript, which con-
trols expression of the adjacent gene Myocardin. Myocardin is
an important co-factor for serum response factor (SRF), a critical
TF implicated in cardiac differentiation [58]. Controlled modu-
lation of Myocardin expression could be envisaged through the
manipulation of this elncRNA. In a regenerative context, iden-
tiﬁcation of lncRNAs with similar characteristics could provide
novel therapeutic avenues to control precursor cell differentia-
tion into particular cardiac cell fates. To identify elncRNAsmore
systematically, very deep RNA-Seq was executed on Poly(A)þ
RNA derived from differentiating mouse ES cells [49]. Ab initio
transcript reconstruction identiﬁed hundreds of multi-exonic
lncRNAs derived from developmental enhancers undergoing
speciﬁc state transitions during cardiac speciﬁcation and differ-
entiation. These ﬁndings have been conﬁrmed by other studies
[59,60]. Altogether, this suggests that the newly identiﬁed
elncRNAs represent interesting candidates to control stage-
speciﬁc differentiation of pluripotent stem cells and/or resident
cardiac precursor cells into cardiomyocytes.Enhancer-associated long noncoding RNAs in the
stressed heart
Considering the emerging roles of enhancer-associated
lncRNAs in numerous pathological settings, the identiﬁcation
and characterization of these transcripts in the diseasedheart is of particular interest. Indeed, the default repair
pathways in the adult heart lead to the formation of a ﬁbrotic
scar and little regeneration. Since these pathways are con-
trolled by gene regulatory networks underpinned by
enhancers and associated elncRNAs, characterizing these
transcripts could offer a means to shift the repair regulatory
network toward a more regenerative avenue. As a ﬁrst step
toward this, we have recently investigated the mouse long
noncoding transcriptome after myocardial infarction using
high-throughput RNA-Seq followed by de novo computa-
tional reconstruction of the mouse transcriptome [32].
Approximately 1500 novel lncRNAs were identiﬁed. Publicly
available data sets were then integrated to functionally
annotate newly identiﬁed lncRNAs. The vast majority were
derived from active heart-speciﬁc enhancers. Those lncRNAs
that were signiﬁcantly modulated post-myocardial infarction
were even more enriched at active cardiac-speciﬁc enhan-
cers, implicating these transcripts in the global transcrip-
tional reprogramming that underpins pathological remodel-
ing. In addition, using novel computational approaches,
many functions were inferred for these lncRNAs based on
their demonstrated chromatin and enhancer state transitions
during the stepwise differentiation of mouse ES cells into
cardiomyocytes. The larger part of the newly discovered
lncRNAs was implicated with cardiac developmental, struc-
tural, and functional gene programs. Bearing in mind that
reactivation of the fetal gene program is a hallmark of the
stressed heart; it is likely that lncRNAs that are modulated
upon damage activate speciﬁc biological processes as an
attempt to induce developmental programs. Targeting elncR-
NAs could therefore promote the dormant regenerative
potential in the injured myocardium. Indeed, one such
lncRNA Novlnc6 was shown to be associated with key
chromatin-state transitions linked to developmental and
maturation cardiac gene programs. Furthermore, modulation
of this elncRNA directly impacted two critical cardiac gene
regulatory proteins, namely the signaling protein BMP10 and
the key cardiac TF Nkx2.5. Importantly, hundreds of predicted
human orthologs of heart-speciﬁc mouse elncRNAs were
identiﬁed. Their expression was differentially modulated in
human cardiac pathologies, such as dilated cardiomyopathy
and aortic stenosis, demonstrating that many lncRNA-
mediated gene networks were conserved in humans. Indeed,
a comparable study has used RNA-Seq for comprehensive
cardiac lncRNA proﬁling in a cohort of patients suffering with
ischemic and non-ischemic heart disease [61]. From a regu-
latory perspective and cogent with previous ﬁndings in
mouse, data suggested enhancer-like cis-regulatory interac-
tions between the lncRNAs and their nearby genes, rather
than trans-regulatory function with distant genes.
Many cardiac enhancers and super-enhancers are not inter-
genic but also located within genes. Such intragenic enhancers
are able to produce functional elncRNAs. An important cardiac
structural gene myosin heavy chain 7 (Myh7) has been recently
shown to produce a lncRNA named Myheart (Mhrt), implicated
in maintaining function in the stressed heart [62]. This lncRNA
is extremely abundant in adult mouse and human hearts.
Pathological stress inhibits Mhrt expression in the remodeling
heart. This repression is critical for cardiomyopathy to develop,
and forced expression of Mhrt is sufﬁcient to protect the heart
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function by antagonizing the activity of Brg1, a chromatin-
remodeling factor previously shown to be responsible for the
aberrant activation of gene expression programs leading to
remodeling and heart failure [63]. Mhrt acts as a molecular
decoy, preventing Brg1 from recognizing and binding its
genomic DNA targets. Interestingly, human MHRT is signiﬁ-
cantly depleted in the hearts of cardiac patients, supporting a
conserved role in human cardiomyopathy.Enhancer-associated long noncoding RNAs in
cardiac regeneration
Our current understanding of the biology of elncRNAs sup-
ports that they represent a new class of molecules playing
key roles in many processes relevant for regeneration,
including speciﬁcation, differentiation, and reprogramming.
A comprehensive identiﬁcation and characterization should
therefore be executed across different developmental stages
and pathological conditions to identify the most relevant
candidates. In particular, such approaches should compare
different models of cardiac regeneration to identify conserved
orthologous regenerative pathways. For instance, it could be
interesting to identify orthologous lncRNAs that are differ-
entially modulated in the Zebraﬁsh heart after ventricular
resection or in the neonatal mouse heart following damage,
two situations in which regeneration relies on proliferation of
dedifferentiate or immature cardiomyocytes [10–12]. Compar-
ing elncRNA proﬁles of orthologs among vertebrates at
corresponding developmental time points will identify
lncRNAs with conserved regulatory functions that can be
translated in human. Then, controlled cardiogenic differ-
entiation of various stem cell types provides model systems
in which to discover new lncRNAs. For example, one could
identify elncRNAs, whose expression correlates with master
regulators of heart development such as Mesp1, Nkx2.5, and
Gata4. Finally, direct reprogramming of non-myocyte cells
such as cardiac ﬁbroblasts into cardiomyocytes represents an
exciting new paradigm for cardiac regeneration [13,29].
Within this context, considering the potential of lncRNAs as
reprogramming factors, proﬁling the enhancer-templated
long noncoding transcriptome to identify elncRNAs that
contribute to this process should be envisaged. Considering
the exquisite cell-, tissue-, and context-speciﬁcity of elncR-
NAs, systemic modulation of gene regulatory networks that
harbor them could be efﬁciently achieved using targeted
depletion with modiﬁed antisense oligonucleotides (ASOs)
[64]. Such therapeutic approaches would minimize detrimen-
tal off-target effects due to intrinsic high speciﬁcity of lncRNA
expression. Furthermore, mechanisms of action of modiﬁed
ASOs, when compared to retrovirus-based strategies, do not
involve genomic insertion or recombination, making these
therapeutic agents ideal for translation in the clinic.Conclusion
We have only recently entered a new era where technology is
forging new frontiers for our understanding of the complexworld of regulatory lncRNAs. The new regulatory layer of
RNAs exhibits integrated activity with other gene regulatory
networks to increase performance and robustness. Enhancer-
associated lncRNAs contribute to enhancer activity and
thereby to targeted gene expression. The ability to modulate
enhancer function via elncRNA knockdown therefore pro-
vides a means for controlling temporal coding gene expres-
sion in vivo in a highly cell-speciﬁc manner. In heart failure
patients, expression of relevant protein-coding genes could
be altered through controlled expression of elncRNAs and
improve outcome. For instance, inﬂammation could be mod-
erated after myocardial infarction by inducing changes in
speciﬁc lncRNA expression in inﬂammatory cells. RNA mol-
ecules such as Myhrt could be therapeutically targeted to
control cardiomyocyte hypertrophy. Similarly, expression of
cardiac ﬁbroblast-speciﬁc elncRNAs could potentially be
modulated to reduce ﬁbrosis. Finally, through manipulating
this new class of regulatory molecules, it might also be
possible to switch the pathological reparative response to
more regenerative healing processes. It is therefore important
to understand the language and function of cis- and trans-
acting elncRNAs. Once this is achieved, we hope to gain
insights into molecular mechanisms controlling tissue repair
and identify new targets for therapeutic intervention. The
ﬁeld of elncRNAs in cardiac disease and regeneration has
unprecedented potential for discovery and will no doubt
remain a rich ﬁeld of research for the coming years.
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